Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $23.02.
Several equities analysts have recently commented on ZYNE shares. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, March 22nd. ValuEngine upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 17th. HC Wainwright restated a “buy” rating on shares of Zynerba Pharmaceuticals in a